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The transcription factor OLIG2 promotes
mitosis of normal and malignant neural
progenitor cells. Zhou et al. have
identified a set of protein kinases that are
both necessary and sufficient to
phosphorylate a key regulatory triple
serine motif in OLIG2. Small inhibitors of
these kinases suppress gliomagenic
functions of OLIG2.
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During development of the vertebrate CNS, the
basic helix-loop-helix (bHLH) transcription factor
Olig2 sustains replication competence of progenitor
cells that give rise to neurons and oligodendrocytes.
A pathological counterpart of this developmental
function is seen in human glioma, wherein Olig2 is
required for maintenance of stem-like cells that
drive tumor growth. The mitogenic/gliomagenic
functions of Olig2 are regulated by phosphorylation
of a triple serine motif (S10, S13, and S14) in the
amino terminus. Here, we identify a set of three
serine/threonine protein kinases (glycogen synthase
kinase 3a/b [GSK3a/b], casein kinase 2 [CK2], and
cyclin-dependent kinases 1/2 [CDK1/2]) that are,
collectively, both necessary and sufficient to phos-
phorylate the triple serine motif. We show that
phosphorylation of the motif itself serves as a tem-
plate to prime phosphorylation of additional ser-
ines and creates a highly charged ‘‘acid blob’’ in
the amino terminus of Olig2. Finally, we show that
small molecule inhibitors of this forward-feeding
phosphorylation cascade have potential as glioma
therapeutics.Cell R
This is an open access article under the CC BY-NINTRODUCTION
A pivotal development in vertebrate evolution was the appear-
ance of myelinating oligodendrocytes that enwrap neural axons
in the CNS. By enabling saltatory conductivity of electrical im-
pulses, oligodendrocytes enabled the vertebrate brain to grow
large and complex. During CNS development, the basic helix-
loop-helix (bHLH) transcription factor Olig2 plays two essential
roles in the formation of oligodendrocytes throughout the CNS.
At late stages of CNS development, Olig2 instructs neural pro-
genitors to exit the cell cycle and adopt an oligodendrocyte
fate. However, at earlier stages of development, Olig2 actually
opposes cell cycle exit and sustains replication competence
so as to allow an adequate pool of oligodendrocyte progenitors
to accumulate (Meijer et al., 2012).
Unfortunately, there is a pathological counterpart of this sec-
ond function. Tumor-initiating cells with stem-like properties
have been isolated from a wide range of adult and pediatric as-
trocytomas (Galli et al., 2004; Hemmati et al., 2003; Ignatova
et al., 2002; Singh et al., 2003). Irrespective of patient age or tu-
mor grade, these stem-like cells are marked by Olig2 (Bouvier
et al., 2003; Ligon et al., 2004, 2007; Lu et al., 2001; Marie
et al., 2001; Ohnishi et al., 2003). Beyond merely marking these
stem-like cells, Olig2 is required for maintenance of the stem-
like state and is essential for tumor formation from intracranial
xenografts of human glioblastomas (Ligon et al., 2007; Mehta
et al., 2011; Suva` et al., 2014). To a large extent, the gliomageniceports 18, 3167–3177, March 28, 2017 ª 2017 The Author(s). 3167
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
functions of Olig2 reflect an oppositional relationship with p53
functions (Mehta et al., 2011). Although p53 signaling is the
most frequently mutated signaling axis in glioblastoma, the ma-
jority of glioblastomas retain at least one intact copy of the p53
gene (Cancer Genome Atlas Research Network, 2008). Com-
plete ablation of p53 in human gliomas or genetically relevant
murine models of glioma eliminates the tumorigenic requirement
for Olig2 (Mehta et al., 2011).
Several years ago, we showed that the mitogenic function of
Olig2 in normal oligodendrocyte progenitors and the anti-p53
functions of Olig2 within stem-like, tumor-initiating cells of gli-
oma are regulated by phosphorylation of a triple serine motif in
the Olig2 amino terminus at S10, S13, and S14. Phosphorylation
of this motif is developmentally regulated and it is the phosphor-
ylated form of Olig2 that has gliomagenic and anti-p53 functions
(Sun et al., 2011). A more recent study demonstrates that this
phosphorylation also regulates the switch from the proliferation
to invasion in glioma cells (Singh et al., 2016). In studies summa-
rized here, we use mass spectrometry (MS), genetics, and test-
tube biochemistry with synthetic peptides to identify a set of
three protein kinases that are collectively both necessary and
sufficient to phosphorylate the triple serine motif. We go on to
show that the motif, when phosphorylated, serves as a template
to prime phosphorylation of three adjacent serines, thus creating
a highly charged ‘‘acid blob’’ in the Olig2 amino terminus. Finally,
we show that small molecule inhibitors of Olig2 protein kinases
might have potential as glioma therapeutics.
RESULTS
Olig2 Is Phosphorylated by GSK3 at S10
We interrogated the Olig2 triple serine motif and flanking amino
acids using four different computer algorithms to identify candi-
date protein kinases for S10, S13, and S14 (Table S1). Small
molecule inhibitors of the most frequent hits in this in silico
screen were tested on Olig2-positive neural progenitor cells
(NPCs) (Table S2). Lysates of the drug-treated cells were size
fractionated by SDS-PAGE and immunoblotted with a phos-
pho-specific antibody that recognizes Olig2 only when all three
members of the triple serine motif are in a phosphorylated state
(Sun et al., 2011). These procedures identified S10 as a potential
substrate for glycogen synthase kinase 3 (GSK3).
In mammals, two isoforms of GSK3 (a and b) share a high de-
gree of homology, particularly in their kinase domain (Doble and
Woodgett, 2003). As shown in Figures 1A and 1B, small molecule
inhibitors of GSK3a/b and also lithium (a well-known GSK3a/b
antagonist) suppress the phosphorylation of Olig2 in cultured
mouse NPCs and also in low-passage human glioma cells (the
BT145 line) that have been maintained under conditions devel-
oped for neural progenitors so as to maintain ‘‘stemness’’ (see
the Experimental Procedures).GSK3a-null mice are viable (Mac-
Aulay et al., 2007), but GSK3b-null mice die at an early stage of
embryonic development (Hoeflich et al., 2000). Accordingly, ge-
netic validation of the GSK3 inhibitor data were achieved in NPC
lines derived from informative intercrosses of GSKa-null and
GSK3b-conditional mice, as shown schematically in Figure 1C.
GSK3a/b double-knockout cells do not survive (Figure 1C),
and immunoblotting assays show no change in phospho-Olig23168 Cell Reports 18, 3167–3177, March 28, 2017levels within GSK3a homozygous null NPCs (Figures 1D and
1E). However, we observe a significant reduction in phospho-
Olig2 levels within GSK3a/+; GSK3b/ NPCs. Together, these
findings indicate that GSK3 function is essential for phosphory-
lation of Olig2 and that GSK3a and b function redundantly
toward this end.
To test whether Olig2 is directly phosphorylated by theGSK3s,
we turned to in vitro kinase assays. As indicated in Figure 1F, the
canonical substrates for GSK3a/b require a ‘‘priming’’ phospho-
serine or phosphothreonine at +4 residues to the carboxyl side.
In its phosphorylated state, S14 of Olig2 would serve this priming
function. As shown in Figure 1G, recombinant GSK3b cannot
phosphorylate an unmodified synthetic peptide corresponding
to residues 1–18 of Olig2. However, an equivalent peptide with
pre-phosphorylated S14 is an excellent substrate. Moreover,
mass spectrometric analysis of the resulting products confirms
that S10 is the enzymatic target of GSK3b in vitro. Besides singly
phosphorylated S14, doubly phosphorylated peptides at S10
and S14 were detected when using phosphorylated S14 pep-
tides as substrates (Figure 1H). Collectively, the data indicate
that S10 of the Olig2 triple phosphoserine motif is phosphory-
lated by GSK3 and this requires pre-phosphorylation at S14.
Olig2 Is Phosphorylated by Casein Kinase 2 at S13
Computer algorithms identified S13 as a potential substrate for
casein kinase 2 (CK2) (Table S1). CK2 functions as a tetramer
composed of two catalytic subunits, CK2a and CK2a0, and two
copies of an essential regulatory subunit, CK2b (Litchfield,
2003). As indicated in Figures 2A and 2B, a small molecule inhib-
itor of CK2 (CX-4945) suppresses phosphorylation of Olig2 in
murine NPCs and also in human glioma cells. Genetic validation
of CK2 as an Olig2 kinase was achieved by using small hairpin
RNA (shRNA) knockdown of CK2b, as shown in Figures 2C
and 2D.
Canonical substrates for CK2 require priming by negatively
charged amino acids such as aspartic acid (D), glutamic acid
(E), or a phosphoserine (pS), positioned at either +1 or +3 resi-
dues to the carboxyl side (Figure 2E) (Meggio and Pinna,
2003). The primary sequence of Olig2 suggests that either E16
or phosphorylated S14 would prime S13 to be phosphorylated
by CK2, and this prediction is borne out by in vitro kinase assays
with recombinant CK2 showing that (1) S13 is a direct enzymatic
target for CK2 and (2) CK2 phosphorylation of Olig2 at S13 is
facilitated by pre-phosphorylation of S14 (Figures 2F and 2G).
Of interest, mass spectrometric analysis of CK2-phosphorylated
Olig2 peptides revealed that S3 is also a substrate for CK2,
which is likely primed by aspartic acid at +1 residue to the
carboxyl side.
Cyclin-Dependent Kinases 1 and 2 Phosphorylate S14
As phosphorylation of the S10 and S13 sites was contingent
upon prior phosphorylation of S14, we focused next on the iden-
tity of the S14 kinase. The S14 site precedes a proline residue,
and phosphorylation of serine in this context is often mediated
by so-called ‘‘proline-directed kinases.’’ The known proline-
directed kinases include mitogen-activated protein kinases
(MAPKs) and cyclin-dependent kinases (CDKs). We focused
on these particular kinase groups because phosphorylation of
Figure 1. GSK3 Phosphorylates Olig2 at S10
(A) Immunoblot assay shows that inhibition of
GSK3 results in reduced Olig2 phosphorylation.
Mouse NPCs and BT145 human glioma cells
treated with GSK3 inhibitors CHIR99021 (CHIR),
SB216763(SB), or LiCl for 4 hr show a decrease in
P-Olig2 level, compared to control cells that were
treated with either DMSO or NaCl. The following
concentrations were used: 5 mm CHIR, 10 mm SB,
10 mM NaCl, and 10 mM LiCl.
(B) Quantification of immunoblot assay. Relative
P-Olig2/Olig2 levels were quantified and compared
between control and inhibitor-treated groups. Data
were analyzed by the Student’s t test and are rep-
resented as the mean ± SEM. *p < 0.05; **p < 0.01
(n = 3). CHIR, CHIR99021; SB, SB216763.
(C) A schematic diagram shows generation of the
mouse GSK3a- and GSK3b-knockout NPC lines.
Control adeno (Ad) or adeno-Cre (Ad-Cre) virus
was introduced to generate GSK3a- or GSK3b-
knockout NPC lines.
(D) GSK3a and b function redundantly to phos-
phorylate Olig2. P-Olig2 levels were examined
in GSK3a/+, GSK3a/, and GSK3a/+GSK3b/
NPCs.
(E) Relative P-Olig2/Olig2 was quantified and
compared between different groups. Data were
analyzed by the Student’s t test and are repre-
sented as the mean ± SEM. *p < 0.05 (n = 3).
(F) GSK3 consensus motif fits the S10 site upon
phosphorylation at S14. pS, phosphorylated
serine; S/T (highlighted in red), the kinase’s target
serine/threonine residue; X, any amino acid.
(G) In vitro kinase assay shows that GSK3 phos-
phorylates Olig2 N-terminal peptide; however, it
requires a priming phosphorylation at S14. Syn-
thetic Olig2 N-terminal peptides (aa 1–18) were
used, and both unphosphorylated Olig2 N-termi-
nal peptide (unPO4) and phosphorylated peptide
at S14 (pS14) were tested. Reactions without
peptides (none) served as negative control. Data
were analyzed by the Student’s t test and are
represented as the mean ± SEM. **p < 0.01 (n = 3).
aa, amino acid; counts per minute (CPM).
(H) Mapping the GSK3 phosphorylation sites
by MS analysis. In vitro kinase reactions were
analyzed by MALDI-MS and –MS/MS. The doubly
phosphorylated peptide at S14 and S10 is indi-
cated by pS14/S10. m/z, mass-to-charge ratio.Olig2 is observed only in cycling or replication-competent cells
(Sun et al., 2011).
As shown in Table S2, small molecule inhibitors of three major
MAPKs, extracellular signal–regulated kinase 1/2 (ERK1/2), p38
MAPKs, and c-Jun N-terminal kinase (JNK) have no impact on
the phosphorylation state of Olig2 in cycling NPCs. However,
a subset of small molecule CDK antagonists suppresses Olig2
phosphorylation in murine NPCs and in the BT145 human gli-
oma cell line. The active subset is confined to inhibitors that
suppress the function of CDK1 and CDK2, whereas inhibitors
active on other CDKs but not CDK1/2 show little or no activity
on Olig2 phosphorylation (Figures 3A and 3B; Table S2).
In these assays, phosphorylation of retinoblastoma protein
(RB) served as a positive control for all CDK antagonists.Accordingly, CDK1 and CDK2 were singled out for genetic
and biochemical validation.
For genetic validation, we first generated CDK2-null NPC lines
from E13.5 embryos of CDK2-knockout mice (Berthet et al.,
2003). As indicated in Figures S1A and S1B, loss of CDK2 alone
had no effect on Olig2 phosphorylation. Targeted disruption of
CDK1 leads to arrest of embryonic development at a very early
stage (Santamarı´a et al., 2007). We tried chronic CDK1 knock-
down in NPCs by using shRNA targeting CDK1; however, the
CDK1-knockdown cell lines also failed to thrive (data not shown).
We then used an adeno-associated virus (AAV)-mediated
shRNA for acute knockdown of CDK1 in either wild-type or
CDK2-null NPCs. As indicated in Figures 3C and 3D, acute
shRNA knockdown ofCDK1withinCDK2-null NPCs significantlyCell Reports 18, 3167–3177, March 28, 2017 3169
Figure 2. CK2 Phosphorylates Olig2 at S13
(A) Immunoblot assay. Mouse NPCs and BT145
human glioma cells were treated with the CK2 in-
hibitor CX-4945 (20 mM) for 4 hr. Cell lysates were
size fractionated by PAGE and immunoblotted
with P-Olig2 and Olig2 antibodies.
(B) Quantification of immunoblot assays. Rela-
tive P-Olig2/Olig2 levels were quantified and
compared between control and inhibitor-treated
group. Data were analyzed by the Student’s t test
and are represented as themean ±SEM. *p < 0.05;
***p < 0.001 (n = 3).
(C) Genetic validation of inhibitor data. CK2b was
knocked down in WT mouse NPCs by lentiviral
vectors that express shRNAs targeting mCK2b.
Cells that were stably transduced with lentivirus
that encode non-target shRNA served as a control
(shConr).
(D) Quantification of knockdown data. Relative
P-Olig2/Olig2 levelswere quantified and compared
between the knockdown group and control group.
Data were analyzed by the Student’s t test
and are represented as themean ±SEM. *p < 0.05;
**p < 0.01 (n = 3).
(E) CK2 consensus motif fits S13 site. D, aspartic
acid; E, glutamic acid; pS, phosphorylated serine;
S/T (highlighted in red), the kinase’s target serine/
threonine residue; X, could be any amino acid.
(F) In vitro kinase assay demonstrates that CK2
phosphorylates the Olig2 N-terminal peptide, and
this phosphorylation is facilitated by the phos-
phorylation of S14. Synthetic Olig2 N-terminal
peptides (aa 1–18) were generated without phos-
phorylation (unPO4) and with pre-phosphorylation
at S14 (pS14). Reactions without peptides (none)
served as negative control. Data were analyzed by
the Student’s t test and are represented as the
mean ± SEM. **p < 0.01 (n = 3).
(G) Mapping CK2 phosphorylation sites by MS
analysis. In vitro kinase reactions were analyzed
byMALDI-MS and –MS/MS. Peaks shown are pS3
(singly phosphorylated peptide at S3), pS13 (singly
phosphorylated peptide at S13), pS3/S13 (doubly phosphorylated peptide at S3 and S13), pS3/S14 (doubly phosphorylated peptide at S3 and S14), pS13/S14
(doubly phosphorylated peptide at S13 and S14), and pS3/S13/S14 (triply phosphorylated peptide at S3, S13 and S14).reducedOlig2 phosphorylation, while acute knockdown ofCDK1
alone in wild-type cells had no effect on Olig2 phosphorylation
(Figures S1C and S1D). Together, these results indicate that
CDK1 and CDK2 function redundantly for phosphorylation of
Olig2.
Despite repeated efforts, we were unable to establish assay
conditions wherein recombinant CDK1 or CDK2 would function
on synthetic peptides in vitro, which might be due to the short
length of the Olig2 N-terminal peptide used in the assay. Accord-
ingly, we used an in vivo phosphorylation assay with an analog-
sensitive mutant of CDK2 (analogue-sensitive [AS]-CDK2) to
validate Olig2 as a direct substrate for CDK2. The ATP-binding
pocket of this mutant CDK2 can utilize bulky adenine analogs,
such as ATP-g-S as a phosphate donor, and can therefore label
CDK2 substrate with P-g-S (Merrick et al., 2011). Expression
vectors encoding wild-type CDK2 or this analog-sensitive
CDK2, together with V5-epitope-tagged wild-type Olig2 or the
S14G Olig2 mutant, were transfected into 293 cells that do not3170 Cell Reports 18, 3167–3177, March 28, 2017express endogenous Olig2. Incorporation of P-g-S into wild-
type or mutant Olig2 was assessed by anti-thiophosphate ester
antibody. As shown in Figures 3E and 3F, the analog-sensitive
mutant CDK2 can phosphorylate wild-type Olig2, whereas the
phosphorylation level is reduced upon mutation of the S14 site.
These data indicate that S14 is a direct substrate for CDK2.
Phosphorylation of the Triple Serine Motif Enables
Formation of a Hexa-phosphoserine Acid Blob in the
Amino Terminus of Olig2
During the course of this work, our procedures and protocols for
mass spectrometric analysis of Olig2 were refined. Improved
methodology enabled the detection of additional phosphoserine
residues in the amino terminal end of Olig2 at S3, S6, and S9
(Figures 4A and S2). However, as shown in Figure 4A in NPCs
expressing wild-type (WT) Olig2, peptide fragments with these
additional phosphoserine residues were never observed without
phosphorylations within the original S10, S13, and S14 sites.
Figure 3. S14 of Olig2 Is Phosphorylated by
CDK1/2
(A) Mouse NPCs and BT145 human glioma cells
treated with CDK1/2 inhibitors show a decrease in
P-Olig2 level: AZD5438 (CDK1/2/9 inhibitor), R547
(CDK1/2/4 inhibitor), CVT313 (CDK1/2 inhibitor).
P-Olig2 and Olig2 levels were examined 4 hr after
AZD5438 and R547 treatment or 24 hr after
CVT313 treatment in NPCs and 3 hr after CVT313
treatment in BT145 cells. The following concen-
trations were used: 10 mm AZD5438, 5 mm R547,
and 10 mM CVT313.
(B) Mouse NPCs treated with CDK4/6 inhibitor,
PD0332991, show no obvious change in P-Olig2
level. P-Olig2 and Olig2 levels were examined 4 hr
after PD0332991 treatment.
(C) Genetic validation of CDK1/2 inhibitor data.
The immunoblot assay shows that knockdown of
CDK1 in CDK2-knockout NPCs decreases the
P-Olig2 level. CDK1 was acutely knocked down
in CDK2-knockout NPCs by introducing AAV
that expresses shRNA targeting mCDK1. Cells
transduced with AAV that expresses non-target
shRNA served as a control (shConr). P-Olig2 and
Olig2 levels were examined at 48 hr after viral
transduction.
(D) Quantification of knockdown data. Relative
P-Olig2/Olig2 levelswere quantified and compared
between the knockdown group and control group.
Data were analyzed by the Student’s t test and are
represented as the mean ± SEM. *p < 0.05 (n = 3).
(E) An analog-sensitive kinase assay shows that
CDK2 phosphorylates Olig2 at the S14 site.
(F)Quantification of analog-sensitive kinaseassays.
Thiophosphorylated Olig2 levels were quantified,
normalized to total Olig2, and then compared
between different groups. Data were analyzed
by two-way ANOVA with the Sidak post test and
are represented as the mean ± SEM. *p < 0.05;
**p < 0.01 (n = 4).The relationship of S3, S6, and S9 to the phosphorylation state
of the original triple serine motif was assessed in a set of ‘‘con-
tingency’’ assays. Olig2-null NPCs were transduced with lentivi-
ral expression vectors encoding Olig2 mutants with informative
phospho-null substitutions at S10, S13, or S14. As shown in Fig-
ure 4A, ablation of the original triple serinemotif completely elim-
inates phosphorylation at S3, S6, and S9. Phospho-null substitu-
tions at S13 and S14 ablate the phosphorylation of S10 and
likewise ablate phosphorylation of S6 and S9. Finally, a single
S/G substitution at S14 almost completely eliminates phos-
phorylation at S10 and S13, although there is a low level of
‘‘breakthrough’’ phosphorylation events to the amino terminal
side. This is consistent with the CK2 kinase assay, which sug-
gests that S13 and S3 can be phosphorylated even with the
absence of S14 phosphorylation, although the efficiency is rela-
tively low (Figures 2F and 2G).
The contingency relationships of S10 and S13 to the phos-
phorylation state of S14 are predicted by the priming require-
ments of GSK3 and CK2 (see Figures 1 and 2). Moreover, close
scrutiny of the Olig2 amino acid sequence shows that S10 and
S13, when phosphorylated, could themselves serve to prime
S6 and S9 for phosphorylation by GSK3 and CK2. In addition,phosphorylation of S6 would facilitate CK2 phosphorylation on
S3. Thus, as modeled in Figure 4B, phosphorylation of S14 by
the cell cycle-modulated kinase CDK1/2 initiates formation of a
hexa-phosphate acidic domain in the amino terminus of Olig2.
Therapeutic Potential for Small Molecule Inhibitors of
Olig2 Phosphorylation
The phosphorylation state of Olig2 is developmentally regulated,
being high in cycling neural progenitors and low in terminally
differentiated, myelinating oligodendrocytes. Previous studies
have shown that gliomagenic and anti-p53 functions of Olig2
are contingent upon phosphorylation of the triple serine motif
(Sun et al., 2011). The functional relevance of this relationship
to the pathobiology of human glioma is illustrated by an opposi-
tional relationship between phospho-Olig2 and p53 status. As
shown in Figure 5, the phospho-Olig2 content of gliomas with
genetically intact p53 is more comparable to that of cycling
neural progenitors than to myelinating oligodendrocytes and is
significantly higher than that of p53 mutant gliomas.
Are therapeutic opportunities for glioblastoma embedded
in the kinases that phosphorylate the triple serine motif? To
address this question, we turned to the genetically accessibleCell Reports 18, 3167–3177, March 28, 2017 3171
Figure 4. Phosphorylation of the Triple Serine Motif Enables For-
mation of a Hexa-phosphoserine Acid Blob in the Amino Terminus of
Olig2
(A) Summary of mass spectrometric analyses on Olig2 N-terminal phos-
phorylated peptides detected in Olig2-null NPCs that were transduced with
WT, triple phospho null (TPN) (S10A/S13A/S14G), double phospho null
(DPN) (S13A/S14G), or single phospho null (SPN) (S14G) Olig2. Black font,
phosphorylated peptides identified in previous study (Sun et al., 2011);
red font, newly identified phosphorylated peptides in WT-Olig2 sample;
blue font, contingent phospho peptides that are undetectable or barely
detectable inWT-Olig2 sample. +, present; +/, detected but with low level;,
undetectable.
(B) A sequentially priming phosphorylation cascade. A schematic diagram
shows how the triple serine motif creates priming sites for additional phos-
phorylations at S3, S6, and S9 that create a hexaphosphate acid blob in the
Olig2 amino terminus.
Figure 5. Analysis P-Olig2 Levels in a Panel of Glioma Cells with
Either WT p53 or Mutant p53
(A) Immunoblot of P-Olig2 in cycling neural progenitor cells (NPCs), adult
mouse corpus callosum (MCC), and low-passage human glioma cells (BT145
line).
(B) Glioma cell lines with intact p53 have significantly higher level of P-Olig2
than p53 mutant glioma cells. The relative P-Olig2/Vinculin levels were
analyzed and compared in different glioma cell lines. Data were analyzed by
the Mann-Whitney test and are represented as the mean ± SEM. *p < 0.05
(n = 8 p53 WT glioma cell lines [filled circles] and n = 4 p53 mutant cell lines
[filled boxes]).murine NSCs. The anti-p53 functions of Olig2 manifest them-
selves in short-term assays and are quantifiable by suppression
of p21 expression. As shown in Figure 6, small molecule inhibi-
tors of CDK1/2, CK2, and GSK3a/b all trigger elevated expres-
sion of p21. Although these small molecule inhibitors likely sup-
press the phosphorylation of multiple on-target and off-target
protein substrates, the p21 responses shown in Figure 6 are
largely rescued by expression of a triple phosphomimetic3172 Cell Reports 18, 3167–3177, March 28, 2017(TPM) Olig2 (S10D/S13E/S14D), indicating that the drug effects
on p21 expression are channeled, at least in part, through their
action on Olig2.
To assess effects of the kinase inhibitors on cell prolifera-
tion, we used a preclinical murine model of pediatric glioma,
a common Olig2-positive brain tumor of childhood (Bergthold
et al., 2014). Activating mutations within the BRAF serine/thre-
onine protein kinase (BRAFV600E) and homozygous deletion
of Ink4a/ARF co-occur in a subset of World Health Organiza-
tion (WHO) grade II–IV pediatric diffuse astrocytomas (Schiff-
man et al., 2010). Mouse NPCs bearing these two mutations
are tumorigenic, and the resulting tumors recapture the histo-
logical characteristics and cellular markers (e.g., Olig2, glial
fibrillary acidic protein (GFAP), and Nestin) of human pediatric
glioma (Huillard et al., 2012). We therefore utilized this mouse
model to assess therapeutic potential of the triple serine motif
as a drug target. Of the six small molecule kinase inhibitors
studied here, the CK2 inhibitor CX-4945 scored second high-
est on the CNS multiparameter optimization (MPO) algorithm
for brain penetrance (Wager et al., 2010) (Table S3). More-
over, CX-4945 is the only one among the six small molecule
kinase inhibitors currently in clinical trials (Chon et al., 2015).
Accordingly, our studies with this tumor model focused on
CX-4945.
To address brain penetrance of CX-4945, we first monitored
Olig2 phosphorylation in the brains of drug-treated mice. As
shown in Figures 7A and 7B, CX-4945 treatment significantly
reduces P-Olig2-positive cells in the brain of our glioma mouse
model. Next, we sought to determine whether CX-4945 could
inhibit cell proliferation in our tumor model by regulating
P-Olig2 levels. This was addressed by using two knockin lines,
wherein the coding sequence of either WT Olig2 or TPM Olig2
(S10D/S13E/S14D, TPM-Olig2) was introduced into the Olig2
locus. As shown in Figures 7C and 7D, CX-4945 inhibits tumor
cell proliferation, but the growth inhibition is rescued by the
TPM-Olig2 variant. As noted for the studies on p21 expression
(Figure 6), the TPM-Olig2 rescue of proliferation is only partial,
Figure 6. Inhibition of Olig2 Phosphorylation
Enhances p53 Function
(A) Olig2 kinase inhibitors increase the p21 level
through inhibiting Olig2 phosphorylation. Olig2-
null NPCs were transduced with retroviruses that
express either WT-Olig2 or TPM-Olig2. The acti-
vation state of p21 upon kinase inhibitor treatment
was examined and compared between two NPC
lines by western blot analysis. Cells were exam-
ined either after 24-hr treatment with 5 mMCVT313
(CDK1/2 inhibitor) or after 8-hr treatment with
10 mMCX-4945 (CK2 inhibitor) or 5 mMCHIR99021
(GSK3 inhibitor).
(B) Quantification of immunoblot assay. Data were
analyzed by two-way ANOVA with the Sidak post
test. There is a significant difference between WT-
Olig2 and TPM-Olig2 in response to Olig2 kinase
inhibitors. Data are represented as the mean ±
SEM. **p < 0.01; ***p < 0.001 (n = 3).presumably because the impact of a CK2 antagonist such as
CX-4945 is not confined to Olig2.
With respect to tumor growth in vivo, previous studies have
shown that PLX-4720 (a small molecule RAF inhibitor that is
currently in clinical trials for BRAF mutant pediatric astrocytoma;
Penman et al., 2015) prolongs survival of mice that received
intracranial grafts of the tumor cells (Bergthold et al., 2014). As
shown in Figures 7E and 7F, CX-4945, as a single agent, had
no statistically significant impact on survival of mice that were
challenged with the tumor cells. However, CX-4945 cooperated
with PLX-4720 to give a survival benefit that exceeds that deliv-
ered by the RAF inhibitor alone. Collectively, these data suggest
therapeutic potential for drugs that block phosphorylation of the
triple serine motif, either as adjuvants to radiation and chemo-
therapy or in combination with other targeted therapeutics.
DISCUSSION
During development and also in disease, pro-mitogenic/anti-p53
functions of Olig2 are controlled by phosphorylation of a triple
serine motif at the amino terminus of the protein (Mehta et al.,
2011; Sun et al., 2011). Here we identify a set of three protein ki-
nases that are both necessary and sufficient to phosphorylate
the triple serine motif. We go on to show that in its phosphory-
lated state, the triple serine motif serves as a template that en-
ables phosphorylation of an additional three serines including
S9, S6, and S3, generating a hexa-phosphoserine acidic domain
in the Olig2 amino terminus. A broad body of data document the
functional role of acidic domains (a.k.a. ‘‘acid blobs’’ or ‘‘nega-
tive noodles’’) as facilitators of protein-protein interactions that
enable transcription factor function (Banerjee and Kundu,
2003; Cross et al., 2011; Garcı´a-Rodrı´guez and Rao, 1998; Li
and Botchan, 1993; Sigler, 1988). Protein alignment of Olig2
shows complete conservation of the six serines in the amino ter-
minal acid blob among humans, mice, chickens, frogs, and fish
(Meijer et al., 2012). Formation of the Olig2 acid blob is linked
to the cell cycle by CDK1/2-mediated phosphorylation of S14.The three kinases that phosphorylate the triple serine motif are
broadly expressed, and direct evidence of their developmental
functions in the formation of Olig2-dependent cell types is lack-
ing. However, targeted disruption of the CK2 regulatory subunit
CK2b in embryonic stemcells does recapitulate some features of
the Olig2-null mouse, including compromised NPC proliferation
and oligodendrogenesis (Huillard et al., 2010).
On a more practical note, a broad body of data suggest that
Olig2 would be an attractive target for glioma therapeutics (Ligon
et al., 2007; Mehta et al., 2011; Suva` et al., 2014). Olig2-null
mouse embryos develop to term but die within minutes following
birth, due to a total deficit of motor neurons (Lu et al., 2002; Zhou
and Anderson, 2002). However, ablation of Olig2 in the postnatal
mouse brain is survivable for extended periods of time (Cai et al.,
2007). Moreover, as a glioma therapeutic, an Olig2 antagonist
might be required only transiently as an adjuvant to standard-
of-care therapeutics. Transcription factors per se are difficult tar-
gets for drug development because their interactions with DNA
or co-regulator proteins tend to involve large surface areas.
However, protein kinases lend themselves well to development
of targeted therapeutics. Does the Olig2 acid blob constitute a
therapeutic opportunity for glioma?
Data generated with small molecule inhibitors of the triple
serine motif kinases can be correlated with a mutational analysis
conducted by Sun et al. (2011). Using site-directedmutagenesis,
Sun et al. (2011) found that a triple phospho-null mutation (S10G/
S13A/S14A) had a severe proliferation phenotype and a double
phospho-null mutation (S13A/S14G) had a partial proliferation
phenotype, whereas a single phospho-null substitution at S14
(S14G) had no discernable impact on cell proliferation. The
lack of a phenotype with the S14G mutation is somewhat at
odds with the pivotal role of S14 as ‘‘the first domino’’ to fall
in a sequentially priming, forward-feeding phosphorylation
cascade as shown in Figure 4. However, the negative result
may be explained by the MS data summarized in Figure 4A,
which suggest a low level of ‘‘breakthrough’’ phosphorylation
events to the amino terminal side of the S14G substitution. TheCell Reports 18, 3167–3177, March 28, 2017 3173
Figure 7. Therapeutic Potential of an Olig2
Kinase Antagonist in a Murine Model of
Pediatric Low-Grade Astrocytoma
(A) CK2 inhibition decreases the P-Olig2 level
in vivo. Developing hGFAP-cre; BrafV600E(fl)/+;
Ink4a-Arf/ pups were treated with 25 mg/kg of
CK2 inhibitor CX-4945 intraperitoneally for 5 days
and were analyzed at P14.
(B) Quantification of P-Olig2 immunostaining. Data
are represented as the mean ± SD. *p < 0.05
(n = 3). CC, corpus callosum. Scale bar, 50 mm.
(C) A schematic diagram shows generation of two
BRAFV600E-transformed NPC lines in an Ink4a-
Arf/ background. The two lines express knockin,
epitope-tagged Olig2, wherein the triple serine
motif is either WT (WT-Olig2-BI) or TPM with the
S10D/S13E/S14D substitutions (TPM-Olig2-BI).
Of note, the Olig2-cre driver is used to activate
expression of the BRAFV600E oncogene, while
simultaneously disrupting another endogenous
Olig2 allele (Sch€uller et al., 2008). The resulting
mice exhibit early prenatal lethality, which pre-
cludes further study in postnatal pups.
(D) Proliferation of the TPM-Olig2-BI line is partially
resistant to the CK2 antagonist CX-4945. For
proliferation assays, 5 3 104 cells were seeded at
day 0 and 1 mM CX-4945 was added at day 1. The
cell number was assessed at day 4. Data were
analyzed by the Student’s t test and are repre-
sented as the mean ± SD. *p < 0.05 (n = 3).
(E) A schematic diagram demonstrates orthotopic
transplantation and the treatment regimen (see the
Experimental Procedures).
(F) Combination of BRAF and CK2 inhibitors signif-
icantly improves survival in an orthotopic model of
pediatricglioma.AKaplan-Meier graph is illustrated
and the log-rank test was used to determine the
survival differences between different treatment
groups. *p < 0.05; **p < 0.01 (n = 8).partial loss of proliferative ability exhibited by the double phos-
pho-null substitution at S13/S14 (Sun et al., 2011) is in accord
with the Figure 4A data, showing that double substitution de-
livers a more complete suppression of phosphorylation events
at S3, S6, S9, and S10. It should also be noted that the cells
may adapt to chronic (i.e., genetic) loss of P-Olig2 in ways that
cannot be achieved with acute, drug-induced loss.
Against this genetic backdrop, small molecule inhibitors tar-
geted to any one of the three kinases that are essential to forma-
tion of the acid blob stimulate expression of p21 (a canonical p53
target gene) and this effect is channeled, at least in part, through
phosphorylation of the Olig2 triple serine motif (Figure 6). Among
these kinase inhibitors, the selective CK2 inhibitor, CX-4945, is
orally available and has been on clinical trials for multiple solid tu-
mors. Although it has not been tested clinically in glioma, CK2a
is frequently overexpressed in glioblastoma, particularly in the
classical subtype of glioma (50.7%) (Zheng et al., 2013). In pre-
clinical studies, CK2 demonstrates an important role in regu-
lating glioma cell viability and is necessary for glioma tumorigen-
esis in vivo. Inhibition of CK2 by CX-4945 impairs glioma cell
proliferation in vitro and suppresses human glioma growth in
the xenograph model (Dixit et al., 2012; Nitta et al., 2015; Zheng
et al., 2013). In our study, we further tested CX-4945 in a pediat-3174 Cell Reports 18, 3167–3177, March 28, 2017ric astrocytoma model. As shown in Figure 7, CX-4945 inhibits
proliferation of Olig2-positive tumor cells and cooperates with
a targeted BRAF antagonist to improve survival in a murine
model of BRAF mutant pediatric astrocytoma. Collectively, the
genetic and pharmacologic data suggest that small molecule
inhibitors of the triple serine motif protein kinases could have
therapeutic potential for malignant gliomas, either as standalone




The serine kinase inhibitors used in this study were AZD5438 (CDK1/2/9 inhib-
itor; Selleckchem), R547 (CDK1/2/4 inhibitor; Selleckchem), CVT313 (CDK1/2
inhibitor; EMD Millipore), PD0332991 (CDK4/6 inhibitor; Selleckchem), CX-
4945 (CK2 inhibitor; Selleckchem or Pfizer), CHIR99021 (GSK3 inhibitor; Sell-
eckchem), SB216763 (GSK3 inhibitor; Selleckchem), PLX-4720 (BRAFV600E
inhibitor; Plexxikon), and LiCl (GSK3 inhibitor; Sigma). All of the small molecule
inhibitors were dissolved in DMSO and stock solutions were kept at 20C,
except LiCl, which was dissolved in water and kept at room temperature.
NPC and Human Glioma Cell Culture
Mouse NPCs were isolated from the lateral ganglionic eminence (LGE) of
E13.5–E14.5 embryos. All human glioma cell lineswere provided byDr. Ligon’s
group (Brigham and Women’s Hospital) and were originally derived from Brig-
ham and Woman’s Hospital patients undergoing surgery in accordance with
institutional review board (IRB) protocols. Both NPCs and human glioma cells
were cultured in serum-free medium containing B27 and N2 supplements,
epidermal growth factor (EGF; 20 ng/mL), and basic fibroblast growth factor
(bFGF; 20 ng/mL). Cells were grown on laminin-coated plates to maintain an
adherent monolayer culture for most assays, except for the experiments
shown in Figure 5, where glioma cells were grown as neurosphere cultures.
Animals
All animal handling and procedures were performed according to University of
North Carolina (UNC), Dana-Farber Cancer Institute (DFCI), Northwestern Uni-
versity (NWU) Feinberg School of Medicine, or University of California, San
Francisco (UCSF) guidelines under Institutional Animal Care and Use Commit-
tee (IACUC)-approved protocols.
GSK3-Null NPC Lines
To generate GSK3a/b-null NPC lines, we crossed GSK3a+/; GSK3bfloxP/floxP
male and GSK3a/; GSK3bfloxP/floxP female mice (Kim et al., 2009; MacAulay
et al., 2007; Patel et al., 2008) and derived GSK3a+/; GSK3bfloxP/floxP or
GSK3a/; GSK3bfloxP/floxP NPCs from the LGE of individual E13–E14 em-
bryos. To generate GSK3b-null NPC lines, we infected the above cell lines
with either adenovirus that expresses theCre recombinase gene or adenovirus
only. The ratio of virus to cells was 100:1. Transduced cells were cultured for at
least three passages before examination to ensure complete recombination
for the GSK3b locus.
In Vitro Peptide Kinase Assay
Active kinases, GSK3b and CK2, were purchased from either Promega
(GSK3b, V1991) or New England Biolabs (CK2, P6010L). Peptides that cover
18 amino acids of the N terminus of Olig2 protein were synthesized as either
native peptides or phosphorylated peptides at S14 (Tufts Physiology Core).
For kinase reactions, we mixed active kinase, Olig2 N-terminal peptides
(20mM) and 32P-labeled ATP (3,000 Ci/mmol) in reaction buffer, and then incu-
bated the mixture for 15 min at 30C. Reactions were then blotted onto nitro-
cellulose membrane and washed three times with 150 mM phosphoric acid,
dried, and subjected to liquid scintillation counting. The products of cold pep-
tide kinase assays were subjected to MALDI-MS and tandemmass spectrom-
etry (–MS/MS) analyses to identify the phosphorylation site(s) (see the Supple-
mental Experimental Procedures).
Analog-Sensitive Kinase Assay with CDK2
WT-CDK2 and AS-CDK2 (F80G) were expressed by the p3xFLAG-CMV
(Sigma) vectors. WTOlig2-V5 and S14GOlig2-V5 were cloned into pcDNA
backbone vectors. To test whether CDK2 can phosphorylate Olig2, we trans-
fected 293 cells with WTOlig2-V5 or S14GOlig2-V5 with either WT-CDK2-Flag
or AS-CDK2-Flag. The in vivo phosphorylation assay was performed accord-
ing to a previous protocol with slight modification (Banko et al., 2011) (see the
Supplemental Experimental Procedures).
Olig2 Protein Purification
As described previously, we have cloned full-length and different mutant forms
of Olig2 into the pWZL-blast retrovirus vector (Sun et al., 2011). We generated
mouse NPC lines that stably express either WT or different mutant forms of
Olig2 by transducing Olig2-null NPCs with the appropriate virus. Exogenous
Olig2 proteins contain a V5 tag at the C terminus. For MS analysis, we isolated
the nuclear fraction and purified Olig2 by using anti-V5 agarose affinity gel
(Sigma). The immunoprecipitation (IP) samples were then digested and sub-
jected to nano-liquid chromatography (LC)-electrospray ionization (ESI)-MS
analysis for phospho-Olig2 peptides.
Preclinical Murine Models of Pediatric Low-Grade Astrocytoma
BRAFV600E in the context of Ink4a-Arf/ is a common genetic driver set for
pediatric glioma (Huillard et al., 2012). BrafV600E(fl)/+ mice, Ink4a-Arf/ mice,
and Olig2-cre mice have been described previously (Dankort et al., 2007;
Sch€uller et al., 2008; Serrano et al., 1996). Two knockin mouse lines that ex-
press either WT-Olig2 or TPM-Olig2 (S10D/S13E/S14D) fused to internal ribo-some entry site (IRES)-EGFP cassettes were newly generated through homol-
ogous recombination of the Olig2 locus in embryonic stem cells (ESCs). Of
note, Olig2-cre; BrafV600E(fl)/+; Ink4a-Arf/mice exhibit early prenatal lethality.
However, by intercrossing the above mouse lines (see the schematic in Fig-
ure 7C), we were able to generate Olig2-cre;WT-Olig2-EGFP;BrafV600E(fl)/+;
Ink4a-Arf/ and Olig2-cre;TPM-Olig2-EGFP;BrafV600E(fl)/+; Ink4a-Arf/ em-
bryos and isolate NPCs fromE14.5 LGE. TheseOlig2 knockin cell lines (labeled
WT-Olig2-BI or TPM-Olig2-BI) were used for in vitro proliferation assays.
For in vivo drug tests, we used adenovirus-Cre to activate BRAFV600E
within NPCs isolated from BrafV600E(fl)/+;Ink4a-Arf/ embryos (see the sche-
matic in Figure 7E). 2 3 105 cells were injected into the brains of 6-week-old
immunodeficient (nude) mice as previously described (Hashizume et al.,
2010). Mice were randomly assigned to four cohorts and treated with
20 mg/kg PLX-4720 and/or 25 mg/kg CX-4945 by intraperitoneal injection
for 5 consecutive days (Monday to Friday) for 2 weeks starting 5 days after
transplantation. All mice were monitored daily for the development of symp-
toms related to tumor growth. Mice were euthanized when they exhibited
symptoms indicative of significant impairment in neurological function.
Statistical Methods
Differential levels of P-Olig2 levels in glioma cell lines were analyzed by the
Mann-Whitney test. Two-way ANOVA with Sidak post tests was performed
when analyzing the analog-sensitive kinase assays and when comparing the
response of WT-Olig2 and TPM-Olig2 cell lines to Olig2 kinase inhibitors.
The log-rank test was used to determine the survival differences between
different treatment groups of mice, and Student’s t tests were used to analyze
sample differences in other assays as described in the figure legends. The sta-
tistical values were obtained using GraphPad Prism software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.03.003.
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